CLINICAL_TRIALS
research
· 2026-04-15
Clinical Trial Update: Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia [Phase 3]
Summary
A Phase 3 clinical trial evaluating NBI-1117568 for preventing relapse in adults with schizophrenia is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neurocrine Biosciences | Conditions: Schizophrenia | Phase 3 | Status: RECRUITING